Overall, the efficacies of the ACT study regimens remained excellent (less than 5% rates of genotype-corrected failure) through the course of the study.
We found a rank order in the efficacy of study regimens, DP > AQ+SP > SP, with SP providing no benefit over placebo.
Generally, the study regimens with bimatoprost were well tolerated and no serious adverse events were reported.
The safety profile and pharmacokinetics (PK) of the study regimens were also assessed.
Furthermore, there was considerable variability among individual pigs using particular study regimens.
Study regimens included amphotericin B formulations (n=4), micafungin (n=3), posaconazole (n=2), voriconazole (n=1), and itraconazole (n=10).
Patients were stratified into naïve and experienced to antiretroviral therapy before starting the study regimens.
Symptoms resolved 7 to 9 days after discontinuation of study regimens.
For compliance with study regimens, the questionnaires were administrated at the study site under the supervision of the study nurse.
The safety population includes all randomised patients who received at least one dose of any component of the study regimens.
